Molecular Formula | C17H29NO5 |
Molar Mass | 327.42 |
In vitro study | β-Aminoarteether (SM934;10 µM; 24 hours) treatment directly enhances IL-10 production and suppresses IL-12/23p40 production in primary peritoneal macrophages with IFN-γ stimulation. In vitro, β-Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation. |
In vivo study | β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice. Animal Model: Female NZB/W F1 mice (Six and half months old) Dosage: 1 mg/kg, 3 mg/kg, and 10 mg/kg Administration: Oral administration; daliy; for 3 months Result: Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. |
Biological activity | β-Aminoarteether (SM934 free base) is a Artemisinin derivative with oral activity. Beta-Aminoarteether can be used in the study of inflammatory and autoimmune diseases, such as lupus disease. |
in vitro study | β-Aminoarteether (SM934;10 µM; 24 hours) treatment directly enhances IL-10 production and suppresses IL-12/23p40 production in primary peritoneal macrophages with IFN-γ stimulation. in vitro, β-Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation. |
in vivo study | β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; For 3 months) treatment significantly the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. beta-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice. Animal Model: female NZB/W F1 MICE (Six and Half Months Old) Dosage: 1 mg/kg, 3 mg/kg, and 10 mg/kg Administration: Oral administration; daliy; For 3 months result: Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 MICE. |
Animal Model: | Female NZB/W F1 mice (Six and half months old) |
Dosage: | 1 mg/kg, 3 mg/kg, and 10 mg/kg |
Administration: | Oral administration; daliy; for 3 months |
Result: | Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. |